AcipHex (rabeprazole) is a proton pump inhibitor that decreases the amount of acid produced in the stomach.

AcipHex is used short-term to treat symptoms of gastroesophageal reflux disease (GERD) in adults and children who are at least 1 year old.

AcipHex is used only in adults to treat conditions involving excessive stomach acid, such as Zollinger-Ellison syndrome. Rabeprazole is also used in adults to promote healing of duodenal ulcers or erosive esophagitis (damage to your esophagus caused by stomach acid).

The concern is that like Nexium, rabeprazole has been linked to kidney problems and increased risk of kidney disease.

In December 2014, the FDA updated Aciphex’ label to strengthen warnings about acute interstitial nephritis. This sudden swelling and inflammation in the kidneys results from an allergic reaction to Aciphex. Without treatment, it can lead to kidney failure.

In January 2016, Johns Hopkins’ researchers published a study linking PPIs with higher rates of Chronic Kidney Disease (CKD). The study found that people who use PPIs once or twice daily face a 20-50% increased risk of kidney disease. CKD damages the kidneys by reducing their ability to clean the blood, which can lead to kidney failure.

In April 2015, PPIs were linked to acute kidney injury and nephritis. A study was published by the medical journal CMAJ Open. Researchers analyzed data on 290,000 Canadians who began taking PPIs between 2002 and 2011. They found a 2.5-fold increased risk of acute kidney injury, as well as a tripled increased risk of nephritis.

In short, PPI’s may help with acid reflux but in turn may destroy your kidney more so than any other medication. They can cause the following problems or symptoms:

Kidney failure
Acute Interstitial Nephritis
Chronic Kidney Disease
Kidney inflammation
Renal disease
Bone fractures
Low magnesium
Muscle spasm
Arrhythmia, heart problems and

If you or a loved one has been injured by taking AcipHex call our firm today at 888HDZLAW8 we can help you determine whether or not you have claim.